Glyphic Biotechnologies, Inc. is developing the first truly de novo high-throughput proteome sequencing technology capable of discriminating all 20 AAs and PTMs accurately with single molecule sensitivity.

Glyphic Biotechnologies, Inc. is developing the first truly de novo high-throughput proteome sequencing technology capable of discriminating all 20 AAs and PTMs accurately with single molecule sensitivity.